Last updated 18:35:04
HK$192.70
+94.65%
- Listing price
- HK$99.00
- Open
- —
- High
- —
- Low
- —
- Bid / Ask
- — / —
- Volume
- —
Turnover —View source
DIAGENS-B
0252618AListed醫療健康 · 杭州德適生物科技股份有限公司是一家专注于生物科技领域的公司，主要从事相关产品的研发与销售。
DIAGENS-B (德適－Ｂ) (02526) is a listed Hong Kong IPO. This page brings together the offer price, entry fee, subscription timeline, grey-market context, allotment data and stage-based reference research in one place.
- Offer price
- HK$99.00
- Final offer price
- HK$99.00
- One-lot win rate
- 3.0%
- Proceeds
- HK$791.9M
- Public oversub.
- 1073.4x
Predicted 4.2%
Lot / entry fee 50 shares · HK$5K · Sponsor Huatai Financial
- Offer starts Mar 20
- /Offer closes Mar 25
- /Grey market Mar 27
- /Listing Mar 30Now
SubscriptionDIAGENS-B: subscription-stage reference
The subscription stage draws on the prospectus, sponsor record and early public filings. Allotment results and grey-market prints have not occurred yet.
Earlier stage- Reference rating
- Neutral
- Reference score
- 69.5
- Forecast grey range
- +10.7% – +161.1%
Pre-greyDIAGENS-B: pre-grey-market reference
The pre-grey stage includes published allotment and public oversubscription data. Grey-market prints are not yet reflected here.
Earlier stage- Reference rating
- Neutral
- Reference score
- 74
- Forecast grey range
- +8.9% – +157.3%
Post-greyDIAGENS-B: post-grey-market reference
The post-grey stage includes grey-market price and turnover observations. Listing-day results still follow official trading and company announcements.
Current- Reference rating
- High attention
- Reference score
- 78.5
- Forecast first-day range
- +79.1% – +160.3%
View factors and research
Model forecastListing-day trendPositiveUp probability 95.0%
Published outcome check
First-day resultBig up+111.7%
Our call: Trend call valid
Covered 16/25 core factors
UsedMissingNot yet scorableN/A
Margin oversubscription
High heatOffer size
Good qualityCornerstone lockup
—Post-lockup offer value
—Recent same-rule trend
Neutral trendRecent same-type trend
Strong trendRecent sector trend
Strong trendValuation
Weak appealFundamental quality
Weak qualityGrowth quality
—Profitability
Weak qualityCash runway
High qualityCustomer concentration
High riskCornerstone quality
—Sponsor record
Good recordGreenshoe arrangementNo greenshoe
Stabilizer track record
—A-share pre-grey trend
—A-share listing-day trend
—Public oversubscription
High heatOne-lot win rate
Good heatInternational placing
High heatFinal pricing position
—Actual greenshoe use
—Grey market return
Strong trendThe assessment and probability ranges are informational only and are not investment advice.
AI Research Report
Post-greyThe analysis report for this IPO is being generated.
DIAGENS-B: grey-market trend
DIAGENS-B: predicted allotment
Only key tiers are shown here. Full tiers and other allotment-pattern comparisons are on the allotment-odds page.
- 1 lot
- 4.2%
- A tail · Apply 1,000 lots
- 0.39 lots
- B head · Apply 1,200 lots
- 0.89 lots
- Top hammer
- 2.2 lots
Official 3.0%
Official 0.83 lots
Official 0.9 lots
Official 3.16 lots
Most likely allotment pattern：Larger Pool A applications get less extra allotment；Pool B allotment falls more sharply with sizeView full allotment-odds research
How to read this page
These answers combine this IPO’s published figures with clearly labeled model estimates. They explain how to read the modules above and are not investment advice.
What is the one-lot allotment rate for DIAGENS-B?
Public allotment filings put the official one-lot rate at 3.0%, versus this site's pre-allotment model estimate of 4.2%. It is an observation for a 1-lot application, not a guaranteed result.
What is the difference between A-tail and B-head for DIAGENS-B?
Based on the prospectus's legal application tiers, A-tail is 1,000 lots and B-head is 1,200 lots, representing about HK$5.0M and HK$5.9M of application principal. Official average allotment was 0.83 lots and 0.9 lots, versus pre-allotment model estimates of 0.39 lots and 0.89 lots. Pool A and Pool B are allocated separately, so application size alone does not show capital efficiency.
Can the grey-market price of DIAGENS-B be treated as the listing price?
The compiled grey-market observation is about +95.1%, versus +111.7% on the listing day. Grey-market prints are pre-listing sentiment from public sources, not the official opening price.
Why does DIAGENS-B have three reference ratings?
The current status is "Listed", so start with the post-grey section. Subscription, pre-grey and post-grey each use only the public information available at that point, so the score can change. Labels are high attention / neutral / caution only — informational comparison, not a buy or subscribe call.